

## Convenience Translation

*This version of the Invitation to the Annual General Meeting 2026, prepared for the convenience of English-speaking readers, is a translation of the German original. For purposes of interpretation the German text shall be authoritative and final.*

**Evotec SE**

**Hamburg**

**- ISIN DE 000 566 480 9 -  
- WKN 566 480 -**

**Unique identifier for the event: DE0005664809-GMET-062026**

We hereby invite our shareholders on

**Thursday, 11 June 2026, at 10.00 a.m. (CEST)**

to

**CinemaxX Hamburg-Dammtor**  
Saal 1  
Dammtordamm 1  
20354 Hamburg

to attend the

### **2026 Ordinary General Meeting.**

All members of the Management Board and the Supervisory Board intend to attend the entire General Meeting.

#### **I. Agenda**

The agenda and the proposed resolutions are as follows:

- 1. Presentation of the approved annual financial statements and the consolidated financial statements of Evotec SE as of 31 December 2025, as approved by the Supervisory Board, the management reports for Evotec SE and the Group for the financial year 2025, the report of the Supervisory Board for the financial year 2025 and the comments by the Management Board regarding this information pursuant to Sections 289a, 315a of the German Commercial Code (Handelsgesetzbuch, HGB).**

On 7 April 2026 the Supervisory Board approved the annual financial statements and the consolidated financial statements that had been prepared by the Management Board and so adopted them in accordance with Sec. 172 sentence 1 German Stock Corporation Act (AktG). In line with the statutory provisions the General Meeting will therefore not pass a resolution on this item of the agenda.

The above documents and the Corporate Governance Declaration for financial year 2025 are available online at <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting> from the time the Annual General Meeting is convened and can also be inspected there during the Annual General Meeting.

**2. Resolution discharging the members of the Management Board of liability for financial year 2025.**

The Supervisory Board and the Management Board propose discharging all the members of the Management Board active in financial year 2025 of liability for this period.

**3. Resolution discharging the members of the Supervisory Board of liability for financial year 2025.**

The Supervisory Board and the Management Board propose discharging all the members of the Supervisory Board active in financial year 2025 of liability for this period.

**4. Resolution regarding the election of the auditor of the consolidated financial statements and the auditor of the sustainability report for financial year 2026 and of the auditor for any review of additional financial information during the year**

**4.1** Based on the recommendation of the Audit and Compliance Committee, the Supervisory Board proposes BDO AG Wirtschaftsprüfungsgesellschaft, Hamburg, as auditor of the consolidated and separate financial statements for financial year 2026 and – to the extent that it is carried out – as auditor for the review of the condensed financial statements and the interim management report for the first half of financial year 2026 and the interim financial information for the first and/or third quarter of financial year 2026 and/or for the first quarter of financial year 2027.

**4.2** Based on the recommendation of the Audit and Compliance Committee, the Supervisory Board also proposes to appoint BDO AG Wirtschaftsprüfungsgesellschaft, Hamburg, as auditor of the sustainability report within the meaning of Directive (EU) 2022/2064 (CSRD) for financial year 2026. The election of the auditor for the sustainability reporting for financial year 2026 is proposed as a precaution in the event that the German legislative in transposition of Art. 37 of Directive 2006/43/EC (EU Audit Directive) as amended by Directive (EU) 2022/2464 (CSRD) should require the explicit appointment of this auditor by the general meeting, i.e. should not simply be the responsibility of the auditor of the financial statements in accordance with the German Transposition Act (CSRD Transposition Act).

The Audit and Compliance Committee has declared that its recommendation is free of any undue third-party influence and that it is not subject to any clause restricting its choice within the meaning of Art. 16 (6) of Regulation (EU) No. 537/2014 (EU Audit Regulation)

## **5. Resolution to approve the Remuneration Report 2025**

Section 162 AktG requires the Management Board and Supervisory Board to prepare a remuneration report and present it to the General Meeting for approval in accordance with Section 12a (4) AktG.

In accordance with Section 162 (3) AktG the auditors audited the Remuneration Report for financial year 2025 to ensure that it included the statutory disclosures required by Section 162 (1) and (2) AktG. The auditor's report is included as an annexe to the Remuneration Report.

The Remuneration Report is available online at <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting> from the time the General Meeting is convened. The Remuneration Report will also be available there during the Annual General Meeting.

The Management Board and Supervisory Board propose the approval of the Remuneration Report 2025 prepared and audited in line with Section 162 AktG.

## **6. Resolution on expanding the Supervisory Board and the corresponding amendment to Article 9 (1) of the Articles of Association**

In accordance with Art. 40(2) and (3) Council Regulation (EC) No. 2157/2001 ("SE Regulation"), Sec. 17 (1) SE Implementation Act (SEAG), Sec. 21 SE Investment Act in conjunction with Sec. 20.1 of the "Agreement between the Special Negotiation Body of the employees of Evotec SE and its subsidiaries and Evotec SE on equity investments by employees in Evotec SE" and Art. 9 (1) of the Articles of Association of Evotec SE, the Supervisory Board of Evotec SE is currently composed of six members elected by the Annual General Meeting.

In order to further strengthen the breadth and depth of the expertise represented in the Supervisory Board and to reflect the higher demands made of the effective monitoring and strategic support for the Management Board, the number of Supervisory Board members is to be increased from six at present to seven.

For this reason, the Management Board and the Supervisory Board propose the following resolution:

Article 9 (1) sentence 1 of the Articles of Association is reworded as follows:

*"(1) The company's Supervisory Board consists of 7 members."*

Article 9 of the Articles of Association is otherwise unchanged.

## 7. Resolution on new and re-elections to the Supervisory Board

The period of office of the Supervisory Board Chair Prof. Dr Iris Löw-Friedrich and of Dr Duncan McHale and Wesley Wheeler ends at the close of the General Meeting of Evotec SE on 11 June 2026. The expansion of the Supervisory Board to 7 persons would also create an additional vacancy. New and/or re-election by the General Meeting for these Supervisory Board positions is therefore required.

In accordance with Art. 40(2)(3) Council Regulation (EC) No. 2157/2001 of 08 October 2001 on the statute for a European company ("**SE Regulation**"), Sec. 17 SE Implementation Act (**SEAG**), Sec. 21 SE Involvement Act ("**SEBG**"), Sec. 20.1 of the "Agreement between the Special Negotiation Body of the employees of Evotec AG and its subsidiaries and Evotec AG on equity investments by employees in Evotec SE" and Art. 9 para. 1 of the Articles of Association, the Supervisory Board of Evotec SE will be - subject to the proposed expansion of the Supervisory Board under agenda item 6 - composed of seven members elected by the Annual General Meeting without being bound by proposals for election.

The Supervisory Board of Evotec SE has defined concrete targets for its composition and drawn up a corresponding competence profile reflecting the company's specific situation. These should be taken into account when making proposals for election to the Supervisory Board to the Annual General Meeting. According to the targets, and taking the company's specific situation into account, the majority of Supervisory Board members should have national and international experience, also in research and development, including biologics, biotech and biopharma, marketing and sales, finance, capital markets, law and corporate governance, sustainability, digitisation, IT and cyber-security. A full overview of the necessary competences can be found in the 2025 Declaration on corporate governance, which is accessible online at <https://www.evotec.com/company/sustainability/governance>.

Mr Roland Sackers has the necessary expertise in financial reporting and auditing of the financial statements required by Art. 9 Abs. 1 lit. c) SE-VO, Section 100 (5) AktG and Principle 15 of the German Corporate Governance Code. Ms Macapili also has expertise in financial reporting. Both elected members remain on the Supervisory Board, so the requirements of Art. 9 Abs. 1 lit. c) SE-VO, Section 100 (5) AktG are satisfied with the existing competences.

Potential conflicts of interest should also be averted by examining the candidates for the Supervisory Board very closely when they are selected. Furthermore, the Supervisory Board should ensure that potential candidates are not older than 72 years of age when they are proposed for election. An appropriate proportion of women is also required. In accordance with Art. 9 (1) lit. c) SE Regulation, Section 111 (5) sentence 1 AktG, the Supervisory Board has temporarily defined the target for the proportion of women on the Supervisory Board of Evotec SE as at least 28%, which must be achieved no later than 31.12.2030; going forward, the aim is to increase the figure again to above 30%. In addition, the Supervisory Board has defined twelve years in office as the regular limit for membership of the Supervisory Board. Exceptions to this are possible by resolution of the General Meeting, however. The Supervisory Board is to be composed in such a way that the majority of its members are independent and collectively have the knowledge, skills and functional experience to carry out their tasks properly.

Considering these concrete targets for the composition of the Supervisory Board and the competence profile for the entire board, the Supervisory Board proposes to elect the candidates listed below in alphabetical order to the Supervisory Board of Evotec SE as follows:

- The person named below in section 7.1, in accordance with Article 9(2) of the Articles of Association, effective from the close of the Annual General Meeting on June 11, 2026, until the close of the Annual General Meeting that decides on the discharge of the members of the Supervisory Board for the 2027 fiscal year (i.e., for approximately two years);
- the person named below in section 7.2, in accordance with Article 9(2) of the Articles of Association, effective from the close of the Annual General Meeting on June 11, 2026, until the close of the Annual General Meeting that decides on the discharge of the members of the Supervisory Board for the 2028 fiscal year (i.e., for approximately three years);
- to elect the person named below in 7.3 as a member of the Supervisory Board of Evotec SE pursuant to Article 9(2) of the Articles of Association, effective from the close of the Annual General Meeting on June 11, 2026, until the close of the Annual General Meeting that resolves on the discharge of the members of the Supervisory Board for the fiscal year 2027 (i.e., for approximately two years);
- The person named below under 7.4 is proposed to be elected as a member of the Supervisory Board of Evotec SE, effective from the date the amendment to the Articles of Association proposed under agenda item 6 takes effect, for a term ending at the close of the Annual General Meeting that resolves on the discharge of the Supervisory Board for the fiscal year 2028 (i.e., for approximately three years).

### **7.1 Dr. Wolfgang Hofmann**

Dr. Wolfgang Hofmann is an internationally experienced manager and licensed physician with more than 25 years of leadership experience in the fields of biotechnology, pharmaceuticals, medical technology, and healthcare services. He combines a solid scientific background in gene therapy and cancer genetics with extensive commercial and entrepreneurial expertise, particularly in corporate strategy, mergers and acquisitions, corporate venture capital, turnaround management, and the successful commercialization of healthcare innovations across multiple markets.

Throughout his career, he has repeatedly stabilized complex organizations, unlocked capital, and driven sustainable, transformative growth. His proven track record includes, among other things, increasing pharmaceutical revenues from approximately EUR 100 million to EUR 500 million, leading comprehensive restructuring and transformation programs within a DAX-listed group, and the successful rescue and repositioning of non-profit institutions.

Dr. Hofmann is the Managing Director of leon-nanodrugs GmbH in Munich. In addition, he is a non-executive board member of Trailhead Biosystems, Cleveland, Ohio, USA (unlisted).

Dr. Hofmann was born in 1968 and is a German citizen.

With his expertise, particularly in corporate turnaround and crisis management, the development and market launch of advanced and innovative therapies, as well as in investor relations, capital raising, and the use of AI-based solutions, Dr. Hofmann ideally complements the range of expertise on the Supervisory Board of Evotec SE.

## **7.2 Dr Duncan McHale**

Dr Duncan McHale has been a member of the Supervisory Board of Evotec SE since 2024. He is a trained medical doctor and has worked in various companies and positions in the life science industry for more than 25 years. Dr McHale is to be elected to the Supervisory Board for another three years. Dr McHale began his career in industry at Pfizer, where he held various management positions from 1999 to 2007, including as European Head Translational Medicine, and in various therapeutic research and development areas. From 2008 to 2011 Dr McHale was Global Head of Translational Science at AstraZeneca, before taking responsibility for research development (clinical phases 1 and 2a) at UCB from 2011 bis 2017. From 2017 to 2023 Dr McHale was Chief Medical Officer at Evelo Biosciences and a Venture Partner at SV Health Investors. Dr McHale founded Weatherden Ltd. in 2017, an advisory company for drug development, which he leads to this day. He has been a guest professor at the University of Liverpool and Kings College London.

Dr McHale currently holds no other positions—apart from his membership on the Supervisory Board of Evotec SE—in any statutory supervisory boards or comparable supervisory boards of economic entities in Germany or abroad within the meaning of Section 125 (1) sentence 5 AktG. His temporarily lower attendance rate of 73% at Supervisory Board meetings in 2025 is due to the fact that he was sometimes unavailable at the extraordinary meetings which were convened at very short notice. Duncan McHale attended all the ordinary meetings and to the extent that he was unable to attend extraordinary meetings, made his opinion known in advance or thereafter.

Dr McHale was born in 1966 and is a British citizen.

His long-standing, extensive experience of the pharma industry and the expertise he gained there, especially in research and development (clinical and pre-clinical) and in business development and governance, are an excellent addition to the range of competences in the Supervisory Board of Evotec SE.

### **7.3 Dieter Weinand**

Dieter Weinand has over 30 years of international leadership and management experience in the pharmaceutical and biopharmaceutical industry. He has held numerous senior management and general management positions at global companies such as Bristol Myers Squibb, Sanofi, Bayer and Pfizer, including full P&L responsibility and the management of international business units.

In recent years Mr Weinand has shifted his focus to non-executive mandates in supervisory boards and boards of directors, particularly at innovative and fast-growing companies. He has extensive experience in the corporate governance of listed companies, including as chair and committee member. His work on the Supervisory Board stands out for its strategic clarity, constructive control of the Management Board and its integrative approach based on long-term value creation.

Mr Weinand has profound functional expertise in key therapeutic areas, including cardiology, oncology, immunology, pneumology, dermatology and inflammatory illnesses. He combines scientific understanding with a pronounced commercial and operational competence – especially in terms of innovation, portfolio strategies, market access and scaling international businesses.

One particular focus of his career is support for transformation and change processes. He has been responsible for numerous international product launches, strategic reorganisations and efficiency programmes and so made significant contributions to increasing profitability, disciplined implementation and strategic focus – topics which are of great importance for MDAX companies in dynamic competitive environments.

His professional work in the USA, Latin America, Asia and Europe enable Dieter Weinand to bring a highly international perspective and a useful global network to the work of the Supervisory Board. He has family connections to Germany, basic knowledge of the German language and a good understanding of German corporate culture and co-determination.

Mr Weinand holds a bachelor's degree in Biology (Concordia College, New York) and a master's degree in Pharmacology and Toxicology (Long Island University, New York).

Dieter Weinand was born in 1962 and is a US citizen.

His long-standing, extensive experience of the pharma industry and the expertise he gained there, especially in transformation and strategy, are an excellent addition to the range of competences in the Supervisory Board of Evotec SE.

If he is elected, the intention is to elect Dieter Weinand to chair the Supervisory Board. He has long-standing experience in senior control and supervisory functions and is currently a member of several supervisory boards, also of publicly listed companies. He no longer has any management functions and assures us that he will find sufficient time for the conscientious performance of his duties as Chair of our company's Supervisory Board. Furthermore, some of his existing mandates are scheduled to expire in the next 12 months. Further information about these mandates and the dates of their expiry can be found in his CV, which is attached to this agenda.

Under these circumstances, the Supervisory Board has come to the conclusion that there is no reason to think the candidate will have excessive demands on his time and that he has the independence and availability required for the position.

#### **7.4. Wesley Wheeler**

Wesley Wheeler has also been a member of the Supervisory Board of Evotec SE since 2024. He has held management positions in the pharma industry for 45 years. Mr Wheeler is to be elected to the Supervisory Board for another three years. Mr Wheeler started as a project engineer at Exxon Research & Engineering (now ExxonMobil). He moved from Exxon to GlaxoSmithKline, where he worked in technology and marketing for 13 years. In his last five years at GlaxoSmithKline he was Senior Vice President of Global Manufacturing & Supply. Wesley Wheeler then moved as CEO to DSM Pharmaceuticals, a department of DSM in the Netherlands, where he was tasked with managing the company through an FDA warning letter and turning it around, which he completed successfully within 15 months. After further stints at Valeant Pharmaceuticals International (now Bausch Health) in global marketing, M&A and research and development, and as CEO of Patheon (now a ThermoFisher company), Mr Wheeler took on the role of CEO at Marken, a leading private logistics company for clinical trials. The turnaround of Marken took five years and led to the sale of the company to UPS in 2016. Marken is now a billion-dollar business and a leading global provider of services for clinical trials. In his final three years at UPS Wesley Wheeler was made President of UPS Healthcare, the first vertical business unit ever established at UPS. Mr Wheeler has been CEO & Board Director at LabConnect, Inc. since 2024. He is also a member of the supervisory boards of the unlisted companies Envirotainer and Argenta. Mr Wheeler has a bachelor's degree in Engineering and a Master of Business Administration. He was a director and CEO of Bushu Pharmaceuticals, which was sold to KKR in 2022.

Mr Wheeler is a member of the board of directors of Envirotainer and Argenta (both unlisted). He is also an investor and a member of the board of directors at Cairn Therapeutics and Belhaven Biopharma (both unlisted).

Wesley Wheeler was born in 1956 and is a US citizen.

His long-standing, extensive experience of the pharma industry and the expertise he gained there, including in research and development, biotechnology, M&A, marketing, sales, operations and governance, make him an excellent addition to the range of competences in the Supervisory Board of Evotec SE.

---

The candidates' curriculum vitae, with information about their relevant knowledge, skills and experience, as well as an overview of their main activities in addition to the Supervisory Board seat, are attached in the annexe to this invitation and can be downloaded from the website <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting>.

There are no personal or professional relations within the meaning of C.7 German Corporate Governance Code between the proposed candidates and Evotec SE or its group companies, the boards of Evotec SE or any shareholder with a significant interest in the company. The proposed candidates are independent. Dr Wolfgang Hofmann is the managing director of leon-nanodrugs GmbH, in which Evotec SE currently holds an equity interest of 3.99%. However, in view of this small stake and the fact that Evotec SE does not have a seat on the supervisory bodies of leon-nanodrugs GmbH, there is no reason to assume a significant business relationship between Evotec and leon-nanodrugs GmbH within the meaning of recommendation C.7. Neither did the Evotec Group generate any revenue with leon-nanodrugs GmbH in 2025 and 2026 (up to the date of this invitation).

The Supervisory Board has ascertained that all the candidates can devote the time expected to be necessary and are not subject to any conflict of interests. If he is elected by the General Meeting the intention is to propose Dieter Weinand as Chair of the Supervisory Board.

The intention is to let the General Meeting decide on the election or re-election the Supervisory Board members by way of an individual vote.

**8. Resolution on creating contingent capital for the issue of subscription rights to Management Board members of Evotec SE, members of management boards of affiliated companies in Germany and abroad and selected managers of Evotec SE and affiliated companies in Germany and abroad as part of a Performance Share Plan 2026 (PSP 2026), based on a resolution of authorisation and amendments to the articles of association.**

To continue to bind executives to Evotec SE and its affiliated companies in Germany and abroad through variable components of compensation with a long-term incentive and share-based risk elements, an opportunity is to be created to issue subscription rights to Evotec SE shares to members of the Management Board of Evotec SE, to members of the executive bodies of affiliated companies in Germany and abroad, and to selected executives of Evotec SE and affiliated companies in Germany and abroad.

The concrete design of the Performance Share Plan 2026 ("PSP 2026") proposed in the resolution is based on the concept of the share performance programme adopted by the General Meeting 2022 and amended by the General Meeting 2025 ("SPP 2022") and is intended to replace it. These performance share programmes are characterised by the fact that participating executives are entitled to a variable remuneration in shares when they achieve demanding targets. In contrast to a conventional stock option programme, when targets are attained, shares are not issued at a price that at least corresponds to the share price of the Company shares at the time of granting the subscription rights, but at the respectively lowest issue amount of currently €1.00, as in the programmes for 2017 and 2022. The main reason for this lies in the fact that in a Performance Share Programme, the entire value of the respective share is used to calculate the value of the remuneration, so making it easier to estimate and more valuable for the participants. There is no special economic advantage in this for the participants, compared with a common stock option programme, since as at the time the subscription rights are granted, and therefore at the outset, it

is taken into consideration that the participants receive the total value of the shares (minus the respectively lowest issue amount of currently € 1.00), and not only, as in regular stock option plans, the difference between the market rate when granting subscription rights and the market rate at issue of the shares. Setting an issue amount of currently € 1.00 is imperative from a corporate law perspective, as the issue of new shares under the respective pro-rata amount of the share capital is not permitted.

For this reason, the Management Board and the Supervisory Board propose that the following resolutions be passed:

**a) Authorisation to issue stock options with subscription rights to Evotec SE shares**

The Management Board, with the agreement of the Supervisory Board, is authorised until 10 June 2031 ("**Authorisation Period**") to set up a stock option programme for members of the Management Board of Evotec SE, members of the executive bodies of affiliated companies in Germany and abroad, and for selected executives of Evotec SE and affiliated companies in Germany and abroad ("**Beneficiaries**"), in the form of a Performance Share Plan (PSP), and to grant, once or repeatedly, subscription rights in the form of "**Performance Share Awards**" to up to 10,000,000 bearer shares with no nominal amount (no-par-value shares) of the Company, with a arithmetic share of share capital of up to €10,000,000.00. One Performance Share Award entitles the bearer to subscribe for up to two Company shares. If Performance Share Awards expire because a Beneficiary leaves Evotec SE or an affiliated company, or because an affiliated company leaves the Evotec Group within the authorisation period, a corresponding number of Performance Share Awards may be re-issued within the Authorisation Period. For the issue of stock options to members of the Management Board of Evotec SE, this authorisation applies solely to the Supervisory Board. A subscription right for shareholders of the Company does not exist. Subscription rights for Company shares are granted and the shares are issued according to the following provisions:

(1) Beneficiaries and distribution

The group of Beneficiaries includes members of the Management Board of the Company ("**Group 1**"), members of the executive bodies of affiliated companies, in Germany and abroad ("**Group 2**"), and selected executives of the Company and affiliated companies in Germany and abroad ("**Group 3**").

The total volume of subscription rights is divided among the individual groups of Beneficiaries as follows:

- Beneficiaries in Group 1 together receive a maximum of 35% of the Performance Share Awards and the resulting subscription rights;
- Beneficiaries in Group 2 together receive a maximum of 5% of the Performance Share Awards and the resulting subscription rights; and
- Beneficiaries in Group 3 together receive a maximum of 60% of the Performance Share Awards and the resulting subscription rights.

If the Beneficiaries simultaneously belong to different groups they only receive Performance Share Awards for their membership of one group.

(2) Issue period (Acquisition period)

Performance Share Awards may be issued within the Authorisation Period in annual tranches. The individual tranches of Performance Share Awards may be offered for purchase to Beneficiaries within a period of three months from the beginning of each calendar year. In addition, Beneficiaries defined in (1) who join the Evotec Group within one calendar year of the Performance Share Awards being issued in the respective calendar year may also be offered at a later date in the calendar year on a one-off basis a pro rata tranche of Performance Share Awards for their entry year. Performance Share Awards must always be issued and, if relevant, exercised after the respective Waiting Period in accordance with the rules on closed periods defined in Regulation No. 596/2016 of the European Parliament and Council of 16 April 2014 (Market Abuse Regulation) and the delegated acts adopted in this context or any legislation replacing them.

(3) Waiting period, term and exercise of subscription rights

Performance Share Awards may only be exercised for the first time after the waiting period has expired. The "**Waiting Period**" for a tranche of Performance Share Awards always starts with the determined issue date, and ends with the expiry of the fourth anniversary after the issue date. The "**Issue Date**" is deemed to be the time at which the Company offers the Performance Share Awards to the Beneficiaries, regardless of the time of receipt, or the acceptance of the offer (*Grant*). Another time within the acquisition period of the respective tranche can be determined as the Issue Date by the offer.

The term of each Performance Share Award is four years (plus the maximum 10-day Exercise Period after expiry of the Waiting Period, see clause (8) below), starting at the Issue Date.

Performance Share Awards that have not been exercised by the end of the period or could not be exercised for reasons for which the Company is not responsible, are exercised automatically without the beneficiary taking any action, by letting the corresponding shares come into existence and then having them sold for the benefit of the beneficiary directly afterwards on the stock exchange by a third party appointed by the company. This constitutes a cash-settled share-based payment. This does not affect the authorisation to re-issue Performance Share Awards that are forfeit prematurely.

(4) Key performance indicators

Performance Share Awards can only be exercised, if and when the two defined *Key Performance Indicators* are achieved, and also depend on performance against the additional ESG target (modifier).

Within each of the key performance indicators set forth below there also is a "**Minimum Target**" that has to be reached for Performance Share Awards to be exercised (partially), as well as a "**Maximum Target**" that, once it is reached, allows for all Performance Share Awards for the respective key performance indicator (100%) to be exercised to the full

amount, i.e. in a ratio of 1:2, after the Waiting Period has expired (one Performance Share Award entitles the holder to subscribe for no more than two whole shares in Evotec SE).

**“Performance Measurement Period”** for the Key Performance Indicators is the three consecutive calendar years, beginning with 1 January of the year in which the individual tranche of the Performance Share Award is issued. Then there is a “Waiting Period” of one further year before the Performance Share Awards can be exercised (see (4) above).

**Key performance indicator “Total Shareholder Return”**

*Total Shareholder Return* is a measure to determine the performance of an investment in the shares of a company. Total shareholder return measures the return on a share investment over a period of time, including dividends as well as share price performance (positive and negative) and adjusted for any equity issues or share-splits.

Achievement for the key performance indicator “Total Shareholder Return” is calculated by taking the Total Shareholder Return figures (average share price on the thirty (30) trading days of the relevant stock exchange immediately preceding the measurement date, plus dividends, adjusted for all equity issuance or stock splits) for Evotec and each company in the peer group, which is made up of relevant competitors from the biotechnology sector and other direct competitors, ranking them and assigning them to a percentile between 0 and 100. If Evotec ranks below the median (50th percentile) the target achievement is 0%. Target achievement of 100% is attained (“**Target Total Shareholder Return**”) when Evotec ranks above the median (50th percentile). If Evotec ranks at the 75th percentile or above, the target achievement is 200%. Higher percentile rankings do not result in a higher target achievement (cap). Target achievement between these figures is calculated by means of linear interpolation.

At the end of the plan period the actual return, the percentile ranking and the resulting payout factor for target achievement are disclosed in the remuneration report.

The composition of the peer group is shown in the following table:

**Relative Total Shareholder Return (TSR) – Industry peer group**

<b>Company</b>		
Bachem Holding	Galapagos	Recursion Pharmaceuticals
Bavarian Nordic	GenScript Biotech	Schrödinger
BioArctic	Genus	Siegfried Holding
BioGaia	Gubra	Tecan Group
Biotest	Kuros Biosciences	Telix Pharmaceuticals
Charles River Laboratories	Ligand Pharmaceuticals	Zealand Pharma

if a significant change occurs at a company in the peer group (e.g. delisting, merger or strategic reorganisation), the Supervisory Board reserves the right to remove this company from the peer group. To ensure that the sector peer group continues to comprise an adequate number of relevant competitors the Supervisory Board may add new

competitors for newly awarded tranches. No additional competitors may be added to the peer group for Performance Share Awards that have already been granted, however. Any changes in the peer group will be disclosed transparently and explained in the remuneration report.

"Performance target **Growth in adjusted Group EBITDA**"

The performance target "Growth in adjusted Group EBITDA" is 100% achieved ("**Target growth in adjusted Group EBITDA**") when the average growth rate in the reported adjusted Group *EBITDA* that has been set is achieved in the performance period taking compounding effects at Evotec SE into account. The performance period is three calendar years. Target growth in adjusted Group EBITDA is based on the average growth in adjusted Group EBITDA in the performance period planned by the Management Board with the approval of the Supervisory Board on the basis of a mid-range plan. The Management Board, with the approval of the Supervisory Board, should generally prepare the mid-range plan for a five-year period every year, on the basis of a sustainable corporate development with demanding, relevant target parameters.

Including growth in adjusted Group EBITDA as a performance indicator is intended to create an incentive for long-term profitable growth and reflect Evotec's sustainable operating focus. The "performance measurement period" is the three-year period starting on 1 January of the year in which the individual tranche of the subscription rights is awarded.

Adjusted Group EBITDA is calculated in accordance with the EBITDA defined and published in the annual report. It is defined as the net profit (net loss), adjusted for interest, taxes, amortisation of intangible assets, impairment losses on goodwill and other tangible and intangible assets, all non-operating earnings, the change in any earn-out payment and items that would distort the presentation of Evotec's financial performance due to their amount, type or occurrence. Adjusted Group EBITDA is shown as an additional performance indicator and is not the same as EBITDA recognised under IFRS.

An ambitious target achievement curve for the performance indicator adjusted EBITDA is used each time Performance Share Awards are granted. At the start of each plan period the Supervisory Board defines the following values for adjusted EBITDA growth on the basis of Evotec's medium-term planning:

- a minimum corresponding to a target achievement of 50%,
- a target corresponding to a target achievement of 100%,
- a maximum corresponding to a target achievement of 200%.

The performance indicator Growth in adjusted EBITDA is measured by reference to the average annual growth rates over the performance period. If the average growth rate at the end of the performance period is the same as the target growth rate defined at the beginning of the performance period, target achievement is 100%.

The minimum target for Growth in adjusted Group EBITDA is achieved when the average growth rate in adjusted Group EBITDA measured over the performance period is at least 50% of the target growth rate defined for this performance period. If the average growth rate at the end of the performance period is the same as the target growth rate defined at the beginning of the performance period (100% target achievement) the payout factor for target achievement is 100%. An average growth rate below the minimum rate results in a target achievement of 0%. Attaining the minimum target achievement results in a payout factor for target achievement of 50%. The Supervisory Board can also define another payout factor for target achievement for reaching the minimum target achievement. If the maximum is achieved or exceeded, the target achievement is 200% (cap). Target achievement between the figures set by the Supervisory Board is calculated by means of linear interpolation. If the minimum target for the performance target "*Growth in adjusted Group EBITDA*" is only not achieved because of the recognised expenses for the Performance Share Plan, these expenses are to be ignored until the minimum target is achieved when the definitive EBITDA amount is calculated for the respective performance period for Group EBITDA.

At the end of the plan period the achievement curve, the actual target achievement and the resulting payout factor are disclosed in the remuneration report.

#### Performance target "**ESG Modifier**"

In addition to the financial performance criteria, the PSP 2026 includes ESG targets via a modifier ranging from 0.8 to 1.2. The ESG targets are intended to set incentives for implementing Evotec's sustainability strategy and to further support the Company's sustainable long-term development.

At the start of each period for a Performance Share Award the Supervisory Board defines ESG targets for each tranche from a catalogue of categories proposed by the Company. The Supervisory Board ensures that the ESG targets are quantifiable and are derived from the sustainability strategy and the materiality assessment.

The ESG modifier is multiplied by the sum of target achievement in the two performance indicators "Total Shareholder Return" and "Growth in adjusted Group EBITDA". The Supervisory Board is authorised to determine the level of target achievement.

(5) Determination of exercisable subscription rights for each performance indicator within a tranche

The following applies to the exercise (also partial) of the number of Performance Share Awards in each tranche that corresponds to each performance indicator:

- (i) If one of the target performance indicators and the target for the ESG modifier are achieved in full (100%) for a performance period, i.e. three calendar years, then 50% of the entire Performance Share Awards in each tranche may be exercised after expiry of the waiting period in a ratio of 1:1, i.e. one Performance Share Award entitles the holder to subscribe for one whole share in Evotec SE.
- (ii) If the maximum target for a performance indicator and the ESG modifier are achieved in full (50%) for a performance period, i.e. three calendar years, then 50% of the entire Performance Share Awards in each tranche may be exercised after expiry of the waiting period in a ratio of 1:2, i.e. one Performance Share Award entitles the holder to subscribe for two whole shares in Evotec SE.
- (iii) If at least the minimum target for a performance indicator is achieved, but not the target performance indicator, then the ratio of subscription rights for the number of Performance Share Awards allocated to this performance indicator that can be exercised after expiry of the waiting period increases on a straight-line basis between 1:0.5 and 1:1 for the performance indicator "Total Shareholder Return" and between 1:0.5 and 1:1 for the performance indicator "Growth in adjusted Group EBITDA". A corresponding linear interpolation (between 1:1 and 1:2) applies if the respective target performance indicator is achieved, but not the maximum target. If the calculation does not produce an integral percentage, the percentage is to be commercially rounded to one decimal place.

(6) Determination of exercisable subscription rights per tranche after the waiting period, limitation of subscription rights

After each of the performance periods for a tranche of Performance Share Awards has ended, the target achievement for the two performance indicators is determined as described for the corresponding four-year period and the corresponding number of subscription rights are calculated and provisionally set. This represents the total number of exercisable subscription rights. If this does not produce a whole number of exercisable subscription rights, the number of exercisable subscription rights is determined by rounding up to the next whole number. Fractional amounts of shares cannot be subscribed and no compensation is paid for any fractional amounts.

The number of subscription rights that can be exercised after expiry of the waiting period may be reduced or forfeit altogether in accordance with any special provisions applying if the Beneficiary's service or employment contract ends before the waiting period expires.

(7) Remuneration cap (only for Group 1, "Management Board")

In the event that the proceeds of selling the exercisable subscription rights calculated as described above at the exercise date, less the exercise price, exceeds the issue value at which the respective tranche was granted by more than 350%, the exercisable number of subscription rights for members of the Company's Management Board is capped so that the sales proceeds obtainable, less the exercise price, do not exceed 350% of the issue value at which the respective tranche was granted. The surplus subscription rights are forfeit without compensation.

In the event of extraordinary, unforeseeable developments, the Supervisory Board may fully or partially limit the content and extent of the subscription rights granted to the members of the Management Board.

(8) Exercise period and exercise price

After expiry of the Waiting Period, Performance Share Awards issued in a tranche and the resulting subscription rights may only be exercised once during the term of the Performance Share Awards.

Subscription rights are exercised automatically via the stock exchange, without the Beneficiary taking any action, by an agent appointed by the Company, over no more than ten (10) trading days after the Waiting Period has expired. For this purpose the Beneficiary must give corresponding instructions to an agent appointed by the Company before the Waiting Period expires. If such instructions are not given in good time, the exercisable Performance Share Awards at the end of the period are exercised automatically without action by the Beneficiary by allowing the corresponding shares to be created and then immediately sold via the stock exchange for the benefit of the Beneficiary by a third party appointed by the Company.

The exercise price has to be paid for each subscribed share when exercising subscription rights. The "**Exercise Price**" per share corresponds to the amount of the share capital attributable to each individual share at the time the subscription rights are exercised, currently €1.00.

(9) Company's replacement right

The company has the right to pay the value of shares to be issued when exercising individual or all subscription rights of individual tranches, minus the Exercise Price, or deliver shares that originate from its treasury, or are acquired for this purpose; in the latter case, the beneficiary's obligation to pay the Exercise Price shall lapse. Otherwise, the above-mentioned provisions remain unaffected.

(10) Personal right

Subscription rights can only be exercised by the Beneficiaries themselves, or their heirs. Subscription rights are legally non-transferable; they can, however, be inherited. Special provisions can be agreed upon in the event of death, retirement, disability, and other special circumstances for departure, including the divestment of affiliated companies, businesses or parts of businesses from the Evotec

Group, and in the case of a change of control, and for the fulfilment of legal requirements, including the pro-rata reduction or forfeiture of the subscription rights exercisable after expiry of the Waiting Period.

(11) Other rules

For the implementation of this resolution toward executives and employees of affiliated companies abroad, the company's Management Board, or if the members of the Management Board are concerned, the Supervisory Board, has the right to deviate from the provisions of the resolution, to the extent that corporation law does not mandate that the content of this resolution be decided by the General Meeting or to the extent that the resolution exceeds minimum requirements under corporation law.

(12) Regulation of details

The Supervisory Board is authorised to determine further details for the granting and fulfilment of Performance Share Awards and resulting subscription rights, and for the issue of shares from the contingent capital increase and further conditions of the PSP 2026, including the determination of conditions for subscription rights, to the extent that members of the Management Board of Evotec SE are affected. Otherwise, the Management Board is authorized to determine these details. These additional details particularly include provisions for consideration or not of special effects of acquisitions or divestments in connection with the measurement of performance targets, provisions for the execution and procedure of granting and exercising subscription rights, the granting of subscription rights to individual Beneficiaries, determination of the Issue Date, determination of the deadline by which the Beneficiary must give instructions to the agent appointed by the Company, as well as provisions for the treatment of subscription rights in special cases, particularly in the event of retirement, death, disability, divestiture of a company, a business, or part of a business from the Evotec Group, or in the event of a change of control, and to meet legal obligations. Conditions for subscription rights shall further contain appropriate provisions for the observation of statutory or Evotec-specific insider-dealing regulations, as well as customary anti-dilution clauses, which essentially secure the economic value of the subscription rights, particularly by taking into account any stock splits, merging of shares, capital increases from company funds with the issue of new shares, decreases of share capital, or other measures with comparable effects for purposes of determining the key performance indicators; in this process, there will be no adjustment of the exercise price.

**b) Contingent capital**

The share capital of the company will be increased by up to €10,000,000.00 through the issue of up to 10,000,000 new bearer shares of the company with no nominal value (no-par-value shares). The contingent capital serves to fulfil subscription rights that were issued and exercised based on the authorisation decided by the General Meeting on 11 June 2026 under agenda item 8. The contingent capital increase will only take place to the extent that holders of subscription rights actually make use of their right to subscribe to Company shares. The issue of shares takes place at the exercise price determined according to agenda item 8 a) (8) of the General Meeting resolution of 11 June 2026 as the

issue amount; § 9, para. 1 AktG remains unaffected.

The new shares are entitled to dividends for the first time for the financial year for which, at the time of their issue, no General Meeting resolution as to the appropriation of the net income has taken place.

The Supervisory Board is authorised to determine further details of the contingent capital increase and its implementation.

The Supervisory Board is further authorised to alter section 5 of the Articles of Association in line with the respective implementation of the capital increase, as well as after expiry of the authorisation or after expiry of the deadline set for exercising the option rights.

### **c) Amendments to the Articles of Association**

Article 5 of the Articles of Association is expanded by the following new paragraph (8):

*"(8) The share capital of the company is increased on a contingent basis by up to €10,000,000.00 through the issue of up to 10,000,000 new bearer shares of the company with no nominal value (no-par-value shares). The contingent capital serves to fulfil subscription rights that were issued and exercised under the Performance Share Plan 2026 to members of the Executive Board, managers and employees on the basis of the authorisation voted by the General Meeting on 11 June 2026 under agenda item 8 a). The contingent capital increase will only take place to the extent that holders of subscription rights make use of their right to subscribe for company shares. The issue of shares takes place at the exercise price determined according to agenda item 8 a) of the General Meeting resolution of 11 June 2026 as the issue amount; § 9, para. 1 AktG remains unaffected. The new shares are entitled to dividends for the first time for the financial year for which, at the time of their issue, no General Meeting resolution as to the appropriation of the net income has taken place.*

*The Supervisory Board is authorised to determine further details of the contingent capital increase and its implementation. The Supervisory Board is further authorised to alter Article 5 of the Articles of Association in line with the respective implementation of the capital increase, as well as after expiry of the authorisation or after expiry of the deadline set for exercising the option rights."*

### **d) Discontinuation of the Share Performance Programmes 2015 and 2017**

No further subscription rights to shares in the Company will be issued to members of the Management Board of Evotec SE, members of the executive bodies of affiliated companies in Germany and abroad, and selected executives of Evotec SE and affiliated companies in Germany and abroad on the basis of the authorisations given according to agenda item 8a) of the General Meeting on 14 June 2017 and agenda item 6a) of the General Meeting on 09 June 2015 to issue subscription rights in the course of the Share Performance Programmes 2015 and 2017. This does not affect subscription rights issued before 11 June

2026. The remaining capital is cancelled and Article 5 (11) and (12) of the Articles of Association are deleted.

**9. Resolution to approve the revised remuneration system for the Management Board**

§ 120a para. 1 AktG stipulates that the general meeting of a publicly listed corporation must pass a resolution approving the remuneration system for Management Board members proposed by the Supervisory Board at least every four years and whenever any material changes are made to the remuneration system.

The Supervisory Board presented a slight adjustment to the previously applicable remuneration system for the Management Board at the General Meeting 2025. The General Meeting 2025 approved this modified remuneration system by a majority of 94.98% of votes cast. After in-depth discussions with shareholders and notwithstanding this approval, the Supervisory Board decided to present a reviewed and revised remuneration system for approval at the Annual General Meeting 2026.

The new Management Board remuneration system is available from our website <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting> from the time the General Meeting is convened. The new remuneration system for the Management Board will also be available there during the Annual General Meeting.

The Supervisory Board therefore proposes the following resolution:

The remuneration system for members of the Management Board, which was adopted, reviewed, and revised by the Supervisory Board on 16 April 2026, is hereby approved.

\* \* \*

## II. Other specifications and comments on the General Meeting

### Documents made available to the shareholders

From the date on which the Annual General Meeting is convened onwards, the following documents are accessible online at <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting>:

- the above documents on agenda item 1
- the Remuneration Report 2025 (agenda item 5)
- CVs of the candidates for the Supervisory Board (agenda item 7.1 to 7.4) and
- the modified remuneration system for Management Board members (agenda item 9)

These documents will also be laid out for review or be available at the General Meeting.

Further information relating to the General Meeting will also be made available at the above address.

### Total number of shares and voting rights

At the time of convening the General Meeting, the Company's share capital amounts to €177,877,782.00. It is divided into 177,877,782 non-par value bearer shares. Each non-par value share grants one vote in the Annual General Meeting. Therefore, the total number of shares and voting rights at the time of convening the Annual General Meeting amounts to 177,877,782 shares and voting rights. No different types of shares exist.

At the time of convening the General Meeting, the Company holds 215,000 treasury shares and 314 ADRs to cover the subscription rights due in 2026 in the context of the long-term incentive programme for the Company's US employees (the US LTI program). The Company has no rights in respect of these shares.

### **Participation at the Annual General Meeting and exercise of voting rights**

Pursuant to Section Article (4) of the Articles of Association, each shareholder is entitled to participate in the General Meeting and exercise his/her voting rights in the General Meeting, who registers with the Company in text form prior to the Annual General Meeting (Section 126b German Civil Code (Bürgerliches Gesetzbuch, BGB)), specifying the number of shares to which the registration relates and proves his/her entitlement to participate in the General Meeting and exercise the voting rights through evidence of share ownership in text form (Section 126b BGB). Evidence of shareholding in text form (Section 126b BGB) from the final intermediary as defined in Section 67c (3) AktG is sufficient. The registration and evidence must be in the German or English language and received by the Company at the following office, under the following address or e-mail address by no later than **midnight CEST on 4 June 2026**:

Evotec SE  
c/o meet2vote AG  
Marienplatz 1  
84347 Pfarrkirchen  
Germany

E-Mail: [anmeldung@meet2vote.de](mailto:anmeldung@meet2vote.de)

In accordance with Sections 123 (4) sentence 2, 121 (7) AktG and Article 15 (4) of the Articles of Association, the evidence of share ownership must relate to the close of business on the twenty-second day before the General Meeting, i.e. **20 May 2026, 24.00 CEST** (the **record date**).

Once the registration and evidence of share ownership have been received, shareholders will be sent admission tickets for the General Meeting and log-in data (ID and password) required to use the password-protected AGM portal (hereafter: "AGM portal") (see section "Password-protected AGM portal") at <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting>. In order to ensure timely receipt of the admission tickets, we request that the shareholders ensure that they send the evidence of their share ownership to the Company at an early stage. The admission tickets, which are either sent by surface mail or made available at the venue of the meeting, are merely intended to assist with the organisation of the Annual General Meeting and are not a requirement for attendance or for exercising one's voting rights.

Registered holders of American Depositary Receipts (ADRs) shall be sent all information and documents related to the Annual General Meeting by J.P.Morgan Chase Bank, N.A., P.O. Box 64504, St. Paul, MN 55164-0504, USA ([jpmorgan.adr@eq-us.com](mailto:jpmorgan.adr@eq-us.com)). If you have any questions regarding the exercise of your voting rights, please contact J.P.Morgan Chase Bank, N.A. at the following phone number: 800 990 1135 (within the USA) or +1 651 453 2128 (from outside the USA).

### **Significance of the record date**

The record date is the crucial date for the scope and exercising of attendance and voting rights at the Annual General Meeting. In relation to the Company, only someone who has provided this record is entitled to attend the Annual General Meeting and exercising their voting rights as a shareholder. The entitlement to attend and the scope of voting rights are exclusively based on the shareholder's share ownership as of the record date. The record date does not mean that the shares may not be sold thereafter. Even in the case of complete or partial sale of the stake after the record date, for the attendance and scope of the voting right, the share ownership by the shareholder as of the record date is exclusively relevant; i.e. sales of share after the record date have no effects on the entitlement to attend and the scope of the voting right. The same applies to additional purchases of shares after the record date. People who do not yet own any shares as of the record date and only become shareholders afterwards are not entitled to attend and vote, unless they receive a power of attorney or are authorised to exercise rights. The record date has no significance for the entitlement to dividends.

### **Password-protected AGM portal**

A password-protected AGM portal is available from 21 May 2026 on the Company's website at <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting>. Registered shareholders (or their proxies) may use this AGM portal to appoint a proxy electronically, to amend or revoke the appointment or to appoint a proxy nominated by the Company and issue voting instructions electronically and to amend or revoke the appointment (see the following sections, "Procedure for voting by proxy" and "Procedure for voting by proxy nominated by the Company"). Access data (log-in ID and password) for the use of the AGM portal will be set to shareholders with the admission tickets for the General Meeting (see above in the section "Participation in the General Meeting and exercise of voting rights").

No rights other than the aforementioned shareholder rights may be exercised via the AGM portal; in particular, no questions may be asked, no requests submitted or objections lodged to resolutions by the General Meeting. The opening of the General Meeting by the chair and the speech by the CEO will be streamed live via the AGM portal.

### **Procedure for voting by a proxy**

Shareholders are informed that their voting right can be exercised in the Annual General Meeting by a proxy, e.g. by an intermediary, an association of shareholders, a voting advisor or another person of their choice. In this case, shareholders must register also themselves and provide evidence of share ownership in due time pursuant to the aforementioned provisions. If a shareholder grants power of attorney to more than one person, the Company can reject one or several of these. This does not affect the option of appointing a separate proxy for the General Meeting for Company shares that a shareholder holds on different securities accounts.

Unless otherwise required by law, the Company must be notified of the proxy, its revocation and evidence of the proxy in text form. For the authorisation of an intermediary, a shareholders' association, a voting advisor or a person, association, institution or entity equivalent to these pursuant to § 135 (8) AktG, special provisions may apply. Shareholders are requested to consult with the proxy in such a case, regarding a possible form of power of attorney that may be required.

In order to send evidence of the proxy appointment by post or email, shareholders or shareholder representatives are requested to use the following address or email address:

Evotec SE  
c/o meet2vote AG  
Marienplatz 1  
84347 Pfarrkirchen  
Germany  
Email: [evotec@meet2vote.de](mailto:evotec@meet2vote.de)

The aforementioned communication methods are also available if the power of attorney is intended to be granted in the form of a declaration to the Company; separate evidence of granting the power of attorney is not necessary in this case. The revocation of an already issued power of attorney can also be declared to the Company using the aforementioned communication methods.

Evidence of a proxy, authorisation by means of a declaration addressed to the Company and the revocation of a proxy must be received by the Company at the above address or email address no later than midnight CEST on 10 June 2026 for organisational reasons.

Evidence of a proxy can be provided to the Company on the day of the General Meeting, regardless of the above deadline, if the proxy shows their authorisation at the door. For the proxy to exercise voting rights this must be done before voting starts. Evidence of the revocation may be provided by the shareholder or another authorised third party on the day of the General Meeting.

A proxy can also be appointed, amended or revoked via the AGM portal at <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting> (see above in the section "Password-protected AGM portal") in accordance with the defined procedure until midnight CEST on 10 June 2026. The access data (log-in ID and password) required to use the AGM portal will be sent with the admission tickets once valid registration has taken place. The proxy must be given the relevant log-in details in order to use the AGM portal.

Shareholders who intend to authorise a representative are requested to use the form made available by the Company for issuing the power of attorney. It will be sent to duly registered persons together with the admission ticket. It can also be requested under the aforementioned address by post or email and is available on the internet at <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting>.

### **Procedure for voting by proxy appointed by the Company**

As a service, we offer our shareholders the possibility of granting power of attorney to instruction-bound proxies who are appointed by the Company.

The shareholders who intend to grant a power of attorney to the proxies appointed by the Company must also register on time as described above, providing the specific evidence of share ownership. Our shareholders will receive a form to appoint a Company proxy and issue voting instructions together with the admission ticket. It can also be requested under the aforementioned address by post or by email and is available on the internet at <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting>.

If the proxies appointed by the Company are granted power of attorney, they must, in any case, be issued with clear instructions for exercising the voting rights with regard to the proposed resolutions. The Company's proxies are obliged to vote in accordance with instructions. If no explicit and clear instructions are given for the proposed resolutions, the proxies will abstain from voting or not take part in the vote. If individual voting is to take place on an agenda item although this was not mentioned before the Annual General Meeting, instructions on this agenda item are deemed to be an instruction for each point of the individual voting. The Company's proxies will not accept any powers of attorney for filing objections against Annual General Meeting resolutions, to exercise the right to speak and ask questions or to file motions.

For organisational reasons, appointing a Company proxy, issuing instructions, amending or revoking them must be notified to the Company at the address or email address provided above in the section "Procedure for voting by a proxy" by no later than midnight CEST on 10 June 2026. Powers of attorney and instructions for the Company proxies may also be appointed, amended or revoked from 21 May 2026 via the password-protected AGM portal at <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting> (see above in the section "Password-protected AGM portal") in accordance with the defined procedure until midnight CEST on 10 June 2026.

After 24.00 CEST on 10 June 2026 power of attorney and voting instructions to Company proxies may only be given if shareholders complete the form attached to the voting documents and hand it in at the door by the time voting at the General Meeting begins.

Appointing a Company proxy does not prevent the shareholder from attending the General Meeting in person. If a shareholder wishes to attend in person or appoint another proxy to exercise their shareholder rights, despite having appointed a Company proxy, then their personal attendance or attendance via a proxy is deemed to revoke the power of attorney given to the Company proxy.

Furthermore, we request the shareholders and shareholder representatives who have registered in the proper form and on time and are present at the Annual General Meeting to also grant power of attorney to the proxies appointed by the Company in the Annual General Meeting.

The corresponding documents are available from the Company website at <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting>.

### **Transmission of information by intermediaries via SWIFT**

In addition to the methods mentioned above for registration, providing evidence of share ownership and voting, registration, evidence of shareholding, proxy appointments, instructions and amendments may also be carried out by intermediaries via SWIFT in accordance with Section 67c AktG. Authorised SWIFT members please use:

BIC: CPTGDE5WXXX

Instructions may only be sent via SWIFT in accordance with ISO 20022.

Registration and evidence of shareholding via SWIFT must be received by the Company no later than the last day of registration (SWIFT Enrolment Market Deadline), i.e. midnight CEST on 4 June 2026. Changes and proxy appointments and voting instructions are still possible after this date via SWIFT and must be received by the Company before midnight CEST on 10 June 2026 (SWIFT Vote Market Deadline).

### Information on shareholder rights

*Right to add items to the agenda pursuant to Art. 56 sentence 2 and 3 SE Regulation, Sec. 50 (2) SEAG, Sec. 122 (2) AktG*

Shareholders, whose shares collectively represent 5% of share capital (corresponds to 8,888,176 shares) or the pro rata amount of € 500,000 (corresponds to 500,000 shares) (the "**minimum interest**") have a right to request that items are added to the agenda and announced. This minimum interest is required in accordance with Art. 56 sentence 3 SE Regulation in conjunction with Sec. 50 (2) SEAG for requests by shareholders of a European company (*Societas Europaea*).

The minimum interest must be proven to the Company, whereby it is sufficient to provide bank certifications. Pursuant to Sec. 50 para. 3 SEAG it is not necessary to have held the shares for ninety days before the date of the Annual General Meeting in accordance with Sec. 122 para. 1 sentence 3 AktG to request an addition to the agenda for a general meeting of an SE.

The request shall be addressed in writing to the Company, represented by the Management Board, whereby each new item for the agenda must include a reason or a proposed resolution. The request for an additional agenda item can also entail a subject for discussion without a resolution. It must be received by the Company by no later than by **midnight (CEST) on 11 May 2026**. Please use the following address or e-mail address (with a qualified electronic signature in accordance with Section 12a German Civil Code (BGB)) to submit your request:

Evotec SE  
– Vorstand –  
Essener Bogen 7  
22419 Hamburg,  
Germany

E-Mail (with qualified electronic signature): [hauptversammlung@evotec.com](mailto:hauptversammlung@evotec.com)

Requests must be received by the Company by the deadline.

Additions to the agenda to be announced, provided that they were not already announced with the convening of the Annual General Meeting, shall immediately be announced after receipt of the demand in the Federal Gazette (Bundesanzeiger) and those publication media that can be assumed to disseminate the information throughout the European Union. They will also be made public on the company website at <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting> and notified to shareholders.

*Opposing motions by shareholders pursuant to Art. 53 SE-VO, Sec. 126 para 1 AktG*

Shareholders are entitled to file motions at the General Meeting opposing a proposal by the Management Board and/or Supervisory Board regarding a specific agenda item.

Under certain circumstances any opposing motions filed by shareholders must be made public on the Company's website before the General Meeting. The opposing motions must be received by the Company in writing or via email by no later than by **midnight (CEST) on 27 May 2026**, including any reasons for them, exclusively at the following address or email address:

Evotec SE  
– Rechtsabteilung –  
Essener Bogen 7  
22419 Hamburg,  
Germany

Email: [hauptversammlung@evotec.com](mailto:hauptversammlung@evotec.com)

Motions that have been otherwise addressed will not be made public. Opposing motions by shareholders that have to be made accessible are made accessible immediately after their receipt, including the name of the shareholder and any grounds for the motion, at <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting>. Possible statements by management in this regard shall also be made accessible at this internet address. The Company can refrain from making an opposing motion and its reason accessible if reasons to exclude it exist pursuant to Section 126 (2) AktG, for example, because the opposing motion would lead to a shareholders' resolution that is illegal or in contravention of the Articles of Association. A reason for an opposing motion does not need to be made accessible if it contains more than 5,000 characters.

We point out that opposing motions and nominations that have been sent to the Company in advance and on time shall only be taken into consideration in the Annual General Meeting if they are submitted orally during the Annual General Meeting.

#### *Proposals for election by shareholders pursuant to Art. 53 SE-VO, Sec. 127 AktG*

Shareholders are also entitled to submit nominations for the election of Supervisory Board members or auditors at the General Meeting. The aforementioned rules on opposing motions apply to them accordingly, with the proviso that the election proposal does not need to have a reason. Over and above the aforementioned reasons for exclusion defined in Section 126 (2) AktG, the election proposal also does not need to be made accessible if it does not include the name, profession and place of residence or place of business of the nominated Supervisory Board member or auditor and in the case of proposals for the election of Supervisory Board members if no information is provided on their membership of other statutory Supervisory Boards.

We point out that opposing motions and nominations that have been sent to the Company in advance and on time shall only be taken into consideration in the Annual General Meeting if they are submitted orally during the Annual General Meeting.

#### *Right to obtain information pursuant to Section 131 (1) AktG*

At the Annual General Meeting, each shareholder and shareholder's representative can request information from the Management Board regarding the Company's affairs, provided that such information is necessary for a proper assessment of the agenda. The obligation to provide information also encompasses the legal and business relationships of the Company to an affiliated Company and the situation of the Group and the companies included in the consolidated financial statements. As a general rule, information requests are submitted orally in the Annual General Meeting, within the context of the debate.

Pursuant to § 16 para 2 Sentence 2 of the Articles of Association, the Chair of the Annual General Meeting is authorised to impose an adequate time limit on the shareholder's right to ask questions and speak. Above and beyond general considerations that may run counter to the information right (e.g. impossibility of providing the information), the Management Board is also entitled to refuse to provide information in specific cases that are regulated in the German AktG Corporation Act (Section 131 (3) AktG), such as if, according to sound commercial judgement, disclosure of the information would inflict a not inconsiderable disadvantage on the Company or an affiliated company.

Further notes on the above shareholder rights can also be found online at <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting>.

### **Streaming of the General Meeting**

The intention is to stream the opening of the General Meeting by the chair and the CEO's speech for registered shareholders and proxies from 10.00 CEST on 11 June 2026 on the AGM portal and to make it available as an audio and video file on the Company's website after the General Meeting.

### **Reference to the Company's website**

The information pursuant to Art. 53 SE-VO, Sec. 124a AktG regarding the General Meeting can be found on the Company's website at <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting>. Any opposing motions, election proposals and additional requests from shareholders that are received by the Company before the General Meeting and have to be made public will also be made available here. The results of the votes shall be announced at the same internet address after the Annual General Meeting.

### **Notes on data protection**

Evotec SE is subject to data protection regulations, and their implementation has a high priority for the Company, in addition to protecting shareholder data. The Evotec SE data protection statement summarises all the information on the processing of shareholders' personal data in a clear and structured form. This data protection statement can be found here: <https://www.evotec.com/ir-news/investor-relations/annual-general-meeting/data-protection-for-shareholders>

Hamburg, April 2026

**Evotec SE**

**Management  
Board**

CVs of the candidates for the Supervisory Board (agenda item 7.1 to 7.4)

**7.1 Curriculum Vitae**

**Wolfgang F. Hofmann, MD**

**Personal data**

Year of birth: 1968

Nationality: German

Independency: yes

**Competences and experiences:**

- Research and Development / Gene Therapy
- Biopharmaceutical Manufacturing
- Biopharma & Medical Technology
- Biotechnology
- Sales
- M&A / Corporate Venture Capital
- Capital Markets & Investor Relations
- Accounting / Income Statement
- Digitalization
- General Management
- Governance
- Corporate Restructuring & Organizational Restructuring
- Commercialization & Scaling Market Entry

**Current occupation:**

Chief Executive Officer, leon-nanodrugs GmbH, Munich, Germany

**Career highlights:**

Since 2025	leon-nanodrugs, Munich, Germany Chief Executive Officer
2024 – Present	Trailhead Biosystems, Cleveland, Ohio, USA Non-Executive Director
2023 – 2024	Fresenius Group, Bad Homburg, Germany Group Head of Technology and Innovation; Chairman, Fresenius Innovation Council (AI and Gene Therapy Boards)
2022 – 2023	Fresenius Group Group Head, Corporate Investments

2021 – 2022	Fresenius Group Head of Group Strategy and Corporate M&A
2019 – 2021	Fresenius Medical Care, Bad Homburg, Germany Global Head of Mergers & Acquisitions
2015 – 2018	Fresenius Medical Care SVP, Head of Integrated Care
2010 – 2015	Fresenius Medical Care CEO, Pharmaceuticals
2006 – 2010	Fresenius Medical Care VP, Pharmaceuticals
2005 – 2012	ANM Adaptive Neuromodulation GmbH, Cologne, Germany Founder, Investor & Board Member (Non-Executive)
1999 – 2005	Novartis, Basel / Atlanta / Frankfurt Various roles in Sales, Marketing, Development, Corporate VC & M&A (Pharma, MedTech & Consumer Health)
1995 – 1999	Dana-Farber Cancer Institute, Boston, USA Research Fellow, Gene Therapy
1995	University of Tuebingen Junior House Officer, Interventional Radiology & Emergency Medicine

**Qualifications:**

1988 – 1995	Heidelberg University Doctor of Medicine (MD)
1999	Harvard Business School Finance & Management
2019	The Johns Hopkins University School of Medicine Healthcare Management / Lean Six Sigma Green Belt Class

**Current group mandates:**

- Trailhead Biosystems, Cleveland, Ohio, USA – Non-Executive Director (not listed)

**Other current mandates:**

- Hoechst Tennis- und Hockey Club 1899, Frankfurt, Germany – President (nonprofit)

**Previous mandates:**

- ANM Adaptive Neuromodulation GmbH, Cologne, Germany –  
Founder, Investor & Board Member (Non-Executive)

*Last update: April 2026*

## **7.2 Curriculum Vitae**

### **Dr Duncan McHale**

#### **Personal data**

Year of birth: 1966

Nationality: British

Independence: yes

#### **Member of the Supervisory Board of Evotec**

First appointment: 2024

Current term of office: General Annual Meeting 2024 – 2026

Committees: ESG Committee

#### **Competences and experiences**

Extensive experience in the Discovery and worldwide Development of medicines with a particular focus on translational medicine, early drug development and Personalized Medicine. Experience at large and medium pharmaceutical companies as well as multiple biotechnology companies. Worked across many therapeutic modalities including small molecule, large molecule, siRNA, cell therapies and oncolytic viruses. Worked across many different disease areas, including immunology, oncology, dermatology, gastroenterology, cardiology, neurology and bone diseases. Experience across multiple biomarker platforms including genetics, transcriptomics, proteomics, metabolomics and imaging. Executive leadership positions in the biopharmaceutical industry for more than 20 years, resulting in progressing over 25 programmes into first-in-human studies. Using a strong scientific background combined with broad clinical research expertise has driven significant changes in early drug development across multiple companies including use of biomarkers, adaptive trial designs, Bayesian statistics and PK PD modelling to inform dose predictions. A long-standing career as an early drug developer and Chief Medical Officer with deep experience in translational medicine and personalized healthcare. Experience of multiple partnership programmes with Pharma partners including membership of multiple steering committees on specific drug programmes and broader multi-company partnerships on technology development. Founded a drug development consultancy organization which has grown to over 40 FTEs in 7 years and as a consultant to multiple biotech companies from 2017 to 2024, have experience of raising capital, buy and sell due diligence, development of corporate strategy, business development strategy and possesses in-depth knowledge and experience in general management, data-enabled innovation and risk management.

Experience as a member of multiple public committees including government advisory committees on human genetics and emerging science and biotechnology as well as Medical Research Committees on stratified Medicine and Clinical Pharmacology. Experience drafting joint industry and regulatory drug development guidelines as a member of the ICH E15 and E16 committees. Have been a member of multiple joint steering committees managing partnerships.

### **Current occupation**

Co-Founder and Senior Development Clinician Weatherden Limited, London, UK  
Chair of Synaptra Bio Ltd

### **Career highlights**

2017 – current	Weatherden Limited Founder and director
2018 – 2023	Evelo Biosciences Chief Medical Officer
2011 – 2017	UCB Pharma Global Head of Exploratory Development
2008 – 2011	AstraZeneca Vice President of Translational Sciences

### **Qualifications**

2010 – 2015	University of Liverpool Professor of Clinical Pharmacology (visiting)
2000	University of Leeds PhD
1990 – 1991	University of Newcastle 1990: B.Med.Sci. (first class) 1991: Bachelor of Medicine and Bachelor of Surgery (medical degree)

### **Current mandates in listed companies**

Evotec SE, Hamburg, Germany (*listed on the Frankfurt Stock Exchange and NASDAQ, New York*)  
Member of the Supervisory Board

### **Previous mandates in public organizations (non-commercial)**

- Member of UK Gov't **Emerging Science and Bioethics Advisory Committee**
- Member of the **UK Human Genetics Commission**
- Chair of **Medical Research Council Stratified Medicine Governance Committee**
- Member of **Medical Research Council Discovery Awards program Committee**
- Member of **Medical Research Council Clinical Training Fellowship (panel)**
- Member of **Medical Research Council Clinical Training Fellowship in Pharmacology (Steering Committee and panel)**

### **Previous Leadership Roles on Industry Committees**

- Chair of the ABPI **UK Stratified Medicine Initiative**
- IMI lead on call for **Molecular Taxonomy of Human Disease**
- Chair of the **EFPIA Pharmacogenetics and Pharmacogenomics ad hoc working group.**
- European Industry Representative to the Genomic biomarker ICH working party and co Rapporteur for **ICH (International Conference on Harmonization) Expert Topic E15 and E16 (Genomic Biomarker Qualification Working group)**

*Last update April 2026*

## 7.3 Curriculum Vitae

### Dieter Weinand

#### Personal data

Year of birth: 1962

Nationality: US-American

Independence: yes

#### Member of the Supervisory Board of Evotec

Designated first appointment: 2026

Designated term of office: 2026 – 2028

#### Competences and experiences

Dieter Weinand brings more than 30 years of leadership experience in the global pharmaceutical and biopharmaceutical industry. He has held senior executive and general management positions at leading multinational companies including Bristol Myers Squibb, Sanofi, Bayer and Pfizer with full P&L responsibility and broad international exposure.

Over the past five years, he has focused on Non-Executive Director roles, primarily supporting innovation-driven biotechnology companies. He has extensive experience in governance and chairmanship responsibilities across public and private organizations and is well regarded for his ability to act as an integrative Chair, providing strategic oversight while constructively supporting executive leadership teams, particularly during periods of transformation or operational challenge.

His sector expertise spans multiple therapeutic areas, including cardiology, oncology, pulmonology, dermatology, immunology, and inflammation. He combines deep scientific and commercial understanding with a strong belief in the strategic value of innovation as a primary driver of long-term company success.

Mr. Weinand has a proven track record in driving change management initiatives, business optimization, and performance improvement on a global scale. He has led major product launches and commercial transformations, strengthening accountability, execution discipline, and portfolio focus across diverse geographies and product lines.

He is known for his high-energy, results-oriented approach and his ability to contribute effectively at board level through strategic insight, independence of thought, and a strong international network of industry stakeholders and investors. Having lived and worked extensively in the United States, Latin America, Asia and Europe, he brings a truly global perspective. He has family ties to Germany, speaks basic German, and has a solid understanding of German business culture.

Mr. Weinand holds a B.A. in Biology from Concordia College, New York, and an M.S. in Pharmacology and Toxicology from Long Island University, New York.

## Current occupation

Professional Non-Executive Board Member of Board of directors in various companies.

## Career highlights

<b>2018 – 2020</b>	<b>Sanofi</b> Executive Vice President, Primary Care
<b>2014 – 2018</b>	<b>Bayer</b> President and Chief Executive Officer, Bayer Pharma
<b>2013 – 2014</b>	<b>Otsuka</b> President, Global Commercialization
<b>2010 – 2013</b>	<b>Pfizer</b>
2012 – 2013	President, Primary Care, Asia Pacific and Canada
2010 – 2012	President, Asia Pacific
<b>2001 – 2010</b>	<b>Bristol Myers Squibb</b>
2009 – 2010	President, Intercontinental
2005 – 2009	President, Latin America, Caribbean and Canada
2004 – 2005	Senior Vice President, Brand Commercialization, Global Marketing
2002 – 2004	Vice President, Neuroscience, Global Brand Champion, Abilify
2001 – 2002	Vice President, Global Marketing, Immunology, Inflammation, Pulmonology and Dermatology

## Qualifications

1985 – 1987	Long Island University, Brooklyn, New York M.S. Pharmacology / Toxicology
1983 – 1984	New York Medical College, Valhalla, New York
1979 – 1982	Concordia College, Bronxville, New York B.A. Biology / Pre-Medicine

## Current Board Affiliations

2018 – present	Replimune Group, Inc. (Public)
2023 – present	Confo Therapeutics NV (Private) (Chair)
2021 – present	Fore Biotherapeutics Inc. (Private) (Chair)
2024 – present	Disco Pharmaceuticals GmbH (Advisory Board) (Private)
2024 – present	Clasp Therapeutics, Inc. (Private) (Chair)
2025 – present	Sibylla Biotech S.p.A. (Private) (Chair)

**Current Boards that will be exited throughout the year 2026:**

2023 – present	Coya Therapeutics, Inc. (Public)
2025 – present	AstriVax Therapeutics NV (Private) (Chair)

**Former Board Affiliations**

2024 – 2026	Anaveon AG (Private) (Chair) (resigned in March 2023)
2025 – 2026 (May)	Orogen Therapeutics, Inc. (Private) (resignation is scheduled as of May 31)
2024 – 2025	Meliora Therapeutics (Private) (Chair)
2021 – 2026	Inspirna Inc. (Private) (Chair)
2021 – 2024	Mnemo Therapeutics SAS (Private) (Chair)
2020 – 2023	Reunion Neuroscience Inc. (Private)
2015 – 2019	HealthPrize Technologies LLC (Private)
2022 – 2024	Umoja Biopharma, Inc. (Private) (Chair)
2020 – 2022	Field Trip Health Inc. (Public)
2020 – 2024	Ziel Bio Inc. (Private)

*Last update April 2026*

## **7.4 Curriculum Vitae**

### **Wesley P. Wheeler**

#### **Personal data**

Year of birth: 1956

Nationality: US-American

Independence: yes

#### **Member of the Supervisory Board of Evotec**

First appointment: 2024

Current term of office: General Annual Meeting 2024 – 2026

Committees: Remuneration Committee

#### **Competences and experiences**

- 20+ years as CEO or President
- Corporate restructuring
- Biologic and small molecule manufacturing
- Drug development & regulatory compliance
- Logistics, depot management and biologic storage
- Clinical laboratory and clinical trials management
- Quality Assurance
- Operational turnarounds
- Marketing
- M&A and corporate integration
- Supply chain operations
- Procurement management
- Lean Six Sigma and Operational Excellence
- Engineering & construction management
- 12 years living / operating in foreign countries

#### **Current occupation:**

2024 – Present

CEO & Board Director, LabConnect Inc.

**Career Highlights:****2019 – 2023****President, UPS Healthcare**

UPS Healthcare Division is a \$10 billion vertical business unit within UPS. The Healthcare Division, comprising 10,000 employees and managing over 17m square feet of GMP space in 35 countries, provides comprehensive logistics solutions - from clinical to commercial - throughout the world.

**2011 – 2019****Chief Executive Officer & Director, Marken, a UPS Company**

Marken is a \$1billion leading specialty clinical supply chain company serving the global pharmaceutical and healthcare industries. Services include central lab specimens logistics, depot storage & distribution, direct to patient services, 4PL management, customs brokerage, kit building and clinical distribution project management. Marken serves 49,000 investigator sites in over 150 countries from 45 worldwide locations. The company was acquired by UPS in December, 2016.

**2007 – 2010****President, Chief Executive Officer & Director, Patheon (now ThermoFisher)**

The pharmaceutical industry's leading contract manufacturing and formulation development company serving the pharmaceutical industry. Publicly traded on the TSX, now privately held and merged with DSM Pharma Products.

**2003 – 2007****President, Valeant Pharmaceuticals International Inc. (now Bausch Health)**

Valeant is a leading specialty pharmaceuticals company. The company manufactures and sells products in several therapeutic categories. During this time, I was responsible for the North American business unit, global marketing, acquisitions and corporate development. Acquired Xcel Pharmaceuticals and several products during this period. I was responsible for the R&D division from 2006-2007, which included the late stage development of retigabine (Potiga).

**2002 – 2003****Chief Executive Officer, DSM (now ThermoFisher)**

DSM is a leading manufacturing company based in the Netherlands. A subsidiary of DSM Pharmaceutical Products, based in Greenville, NC. The Greenville facility employed 1,200 people and was the third largest employer in Pitt County. Many important biological drugs were launched from this site and continue to supply the industry.

**1989 – 2002**

**Senior Vice President – Manufacturing and Supply,  
GlaxoSmithKline**

Responsibilities included the management of strategy and logistics for the global manufacturing & supply division, based in London and RTP. During this period, GSK consolidated all manufacturing, procurement and logistics under one central division and put in place a five year transformational change program which ultimately reduced the cost of goods with few sites and better processes. LeanSixSigma was introduced to GSK twice during this period.

**1978 – 1989**

**Field Engineer, Cost & Schedule Engineer –  
ExxonMobil Corp**

**Qualifications:**

1992

California Lutheran University  
Master of Business Administration, Finance

1974 - 1978

Worcester Polytechnic Institute  
BSME, Mechanical Engineering, with distinction

**Current mandates in listed companies:**

Evotec SE, Hamburg, Germany (*listed on the Frankfurt Stock Exchange and NASDAQ,  
New York*)

Member of the Supervisory Board

**Current mandates in non-listed companies:**

- Envirotainer – Director of the Board
- Argenta – Director of the Board

**Other current mandates:**

- Cairn Therapeutics – Investor / member of the Board
- Belhaven Biopharma – Investor / member of the Board

*Last update: April 2026*

**Minimum information required by Section 125 (1) German Stock Corporation Act (AktG) in conjunction with Section 125 (5) AktG, Article 4 (1) and Table 3 blocks A to C of the Annex to the Implementing Regulation (EU) 2018/1212**

Type of specification	Description
<b>A. Specification of the message</b>	
1. Unique identifier for the event:	DE0005664809-GMET-062026
2. Type of message	Meeting notice [in the format required by Implementation Regulation (EU) 2018/1212: NEWM]
<b>B. Specification of the issuer</b>	
1. ISIN	DE0005664809
2. Name of issuer	Evotec SE
<b>C. Specification of the meeting</b>	
1. Date of the General Meeting	11 June 2026 [in the format required by Implementation Regulation (EU) 2018/1212: 20260611]
2. Time of the General Meeting	10:00 (CEST) [in the format required by Implementation Regulation (EU) 2018/1212: 08:00 UTC]
3. Type of General Meeting	Ordinary General Meeting [in the format required by Implementation Regulation (EU) 2018/1212: GMET]
4. Location of General Meeting	CinemaxX Hamburg-Dammtor, Saal 1, Dammtordamm 1, 20354 Hamburg, Germany
5. Record Date	20.05.2026, 24:00 (CEST) [in the format required by Implementation Regulation (EU) 2018/1212: 20260520]
6. Uniform Resource Locator (URL)	<a href="https://www.evotec.com/ir-news/investor-relations/annual-general-meeting">https://www.evotec.com/ir-news/investor-relations/annual-general-meeting</a>